Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Guerbet
All patients will be followed up during 2 years after Dotarem® administration to collect data on any suspected NSF or NSF-related symptoms
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with moderate to severe and end stage renal impairment or dialysis, scheduled for a contrast-enhanced Magnetic Resonance Imaging (MRI) with Dotarem
You may not be if
Patient who has received a Gadolinium Based Contrast Agent (GBCA) within the past 12 months prior to inclusion in this study except if the GBCA received is Dotarem
